

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

<https://marketpublishers.com/r/D46BA92830DEN.html>

Date: June 2019

Pages: 67

Price: US\$ 3,500.00 (Single User License)

ID: D46BA92830DEN

Abstracts

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

SUMMARY

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Metabolic Disorders, Oncology, Immunology and Musculoskeletal Disorders which include indications Alzheimer's Disease, Down Syndrome, Type 1 Diabetes (Juvenile Diabetes), Autoimmune Disorders, Colon Cancer, Dementia, Depression, Glioblastoma Multiforme (GBM), Lung

Cancer, Osteoarthritis, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Prostate Cancer.

The latest report Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019, outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)

The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC

2.7.12.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development

Involved in Therapeutics Development

Avanti Biosciences Inc

Carna Biosciences Inc

Felicitex Therapeutics Inc

ManRos Therapeutics

NeuroNascent Inc

Pharmasum Therapeutics AS

Samumed LLC

San Biotechnology Co Ltd

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles

ABI-01 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
ABI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adavivint - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-9847 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPO-1143 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-1100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PST-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-07883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate DYRK1A for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecule to Inhibit DYRK1A for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Parkinson's Disease and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant

Products

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones

Featured News & Press Releases

May 02, 2019: Samumed launches phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis

Apr 10, 2019: Samumed announces multiple presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Apr 04, 2019: Samumed doses first subject in phase 1 trial of SM07883, a potential treatment for Alzheimer's Disease

Mar 07, 2019: Samumed to present clinical data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

Feb 28, 2019: Samumed announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in knee osteoarthritis

Jan 29, 2019: Samumed to present novel biological targets of SM04690 for treatment of knee osteoarthritis

Nov 05, 2018: Samumed announces multiple presentations at 6th world congress on controversies, debates & consensus in bone, muscle & joint diseases.

Oct 24, 2018: Samumed phase 2b trial in knee osteoarthritis meets primary endpoints

Oct 18, 2018: Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer's Disease (CTAD) Congress

Oct 16, 2018: Samumed to present data from phase 2b trial of SM04690 for treatment of knee osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting

Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer's Association International Conference

Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer's Disease Candidate, at the Alzheimer's Association International Conference 2018

Jun 29, 2018: Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference

Jun 20, 2018: Samumed Presents Clinical and Preclinical Data at European League

Against Rheumatism (EULAR) 2018 Annual Congress
Jun 08, 2018: Samumed Announces Presentations on SM04690 at the European
League Against Rheumatism (EULAR) 2018 Annual Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Avanti Biosciences Inc, H1 2019
Pipeline by Carna Biosciences Inc, H1 2019
Pipeline by FeliciteX Therapeutics Inc, H1 2019
Pipeline by ManRos Therapeutics, H1 2019
Pipeline by NeuroNascent Inc, H1 2019
Pipeline by Pharmasum Therapeutics AS, H1 2019
Pipeline by Samumed LLC, H1 2019
Pipeline by San Biotechnology Co Ltd, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

COMPANIES MENTIONED

Avanti Biosciences Inc

Carna Biosciences Inc

Felicitex Therapeutics Inc

ManRos Therapeutics

NeuroNascent Inc

Pharmasum Therapeutics AS

Samumed LLC

San Biotechnology Co Ltd

I would like to order

Product name: Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/D46BA92830DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D46BA92830DEN.html>